leisure time -WSS

leisure time

author：comprehensive 2025-10-01 18:23:36 - browse：13

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Telehealth startups are trying to fill the menopause care vacuum

WSS

J&J lung cancer data amount to new salvo against AstraZeneca

Smaller biotechs seek to piggyback on weight loss drug boom

STAT Summit: Meghan O’Rourke on making chronic illness visible

STAT Summit: Ending the crisis of Black deaths in the U.S.

When a patient nears the end, a feared therapy can comfort

STAT Summit: How researchers deal with rejection

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Hepatitis C has a cure — but many Americans still lack access to it

Study on Amgen’s bispecific immunotherapy produces positive data

Apple is now the first public company to be valued at $3 trillion

How a Boston hospital is priming medical residents to use GPT

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Roche acquires Telavant from Roivant, adding experimental IBD treatment

What does generative AI mean for health care? We asked experts

Sanders wants to replace patents with prizes for drug inventions

knowledge

Extensive review finds private equity owners jack up cost of care

Smaller biotechs seek to piggyback on weight loss drug boom

The stock market has soared this year, but will it last? Experts weigh in

ADCs take center stage as promising cancer treatments

J&J lung cancer data amount to new salvo against AstraZeneca

J&J lung cancer data amount to new salvo against AstraZeneca

focus

focus

Wikipedia

entertainment